Eric Swayze sold $236k of IONS
EVP Research at IONIS PHARMACEUTICALS INC. 7,176 shares at an average of $32.84, traded Jan 16, 2025, filed Jan 17, 2025.
Score components
- +15RoleOfficer
- +13Trade size$236k at market
- +5Share of holdings soldSold 14% of holdings
- +15Cluster10 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000874015-25-000065, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 15, 2025 | MOption exercise Common Stock | +19,111 | $0.00 | $0 | 52,824 | Jan 17, 2025 |
| Jan 16, 2025 | SOpen-market sale Common Stock | -7,154 | $32.84 | $235k | 45,670 | Jan 17, 2025 |
| Jan 15, 2025 | MOption exercise Common Stockindirect: by Son | +49 | $0.00 | $0 | 206 | Jan 17, 2025 |
| Jan 16, 2025 | SOpen-market sale Common Stockindirect: by Son | -22 | $32.70 | $719 | 184 | Jan 17, 2025 |
| Jan 15, 2025 | AGrant or award Performance Restricted Stock Unitsderivative | +22,000 | $0.00 | $0 | 64,482 | Jan 17, 2025 |
| Jan 15, 2025 | AGrant or award Restricted Stock Unitderivative | +33,000 | $0.00 | $0 | 79,728 | Jan 17, 2025 |
| Jan 15, 2025 | MOption exercise Restricted Stock Unitderivative | -19,111 | $0.00 | $0 | 60,617 | Jan 17, 2025 |
| Jan 15, 2025 | AGrant or award Restricted Stock Unitderivativeindirect: by Son | +245 | $0.00 | $0 | 671 | Jan 17, 2025 |
| Jan 15, 2025 | MOption exercise Restricted Stock Unitderivativeindirect: by Son | -49 | $0.00 | $0 | 622 | Jan 17, 2025 |
Related signals
Other insiders at IONIS PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | IONIS PHARMACEUTICALS INC | Eugene Schneider EVP, Chf Clinical Develop Ofcr | $412k 5,812 shares | -8% | |
| 47Moderate | IONIS PHARMACEUTICALS INC | Elizabeth L Hougen EVP, Finance & CFO | $16M 225,220 shares | -73% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | Kyle Jenne EVP, Chf GL Pdt Str Ofcr | $2.8M 37,277 shares | -76% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | Brett P Monia Chief Executive Officer | $12M 160,773 shares | -44% | |
| 37Weak | IONIS PHARMACEUTICALS INC | Patrick R. O'Neil EVP CLO & General Counsel | $764k 10,148 shares | -14% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | C Frank Bennett EVP, Chief Scientific Officer | $6.7M 85,089 shares | -51% | |
| 18Weak | IONIS PHARMACEUTICALS INC | Joseph Baroldi EVP, Chief Business Officer | $531k 6,659 shares | -15% | |
| 30Weak | IONIS PHARMACEUTICALS INC | Shannon L. Devers EVP, Chief Human Resources Ofc | $1.6M 20,106 shares | -47% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | Allene M. Diaz director | $4.4M 54,878 shares | -94% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | Joseph Klein III director | $1.7M 21,332 shares | -66% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.